Newron starts a PhII schizophrenia study; FDA accepts an NDA from AbbVie;

@FierceBiotech: Q&A: Philips on what's next after the first year of HealthTech. More from FierceMedicalDevices | Follow @FierceBiotech

@JohnCFierce: Zafgen shares crash after second patient in pivotal obesity study dies. Report | Follow @JohnCFierce

@DamianFierce: Knicks Porzingis jersey not yet for sale so I'm just getting his name tattooed on my back as a placeholder. | Follow @DamianFierce

> Italy's Newron Pharmaceuticals has launched a Phase II study with its novel sodium channel blocker, NW-3509, in patients with schizophrenia. Release

> AbbVie ($ABBV) says that the FDA has accepted its NDA for a once-daily, fixed-dose formulation of the components of Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets). Release

> Ultragenyx's ($RARE) in-development treatment for a rare bone disease improved symptoms in interim results from a Phase II study, the company said. More

> GlaxoSmithKline ($GSK) launched Nucala, an antibody treatment for severe asthma. News

> Researchers at Rockefeller University have hit on a new approach to treating nicotine addiction that could spark new therapies. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Boston Sci receives FDA and CE mark approval of its thrombectomy catheter for deep vein thrombosis. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: AstraZeneca begins dosing in trial of its Bind-partnered cancer candidate. Article | Follow @VarunSaxena2

@EmilyWFierce: $GILD: "Let's not fold to advocacy pressure in 2014." More from the WSJ | Follow @EmilyWFierce

> Syneron Medical bogged down with slumping sales for ultrasound fat-zapping device. Story

> Theranos asked military general for help tamping down 'misinformation' from the DOD. Article

Pharma News

@FiercePharma: FDA approves Seqirus' Fluad, the first U.S. adjuvanted flu vaccine. FierceVaccines story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Bristol-Myers puts a blockbuster $142K price on new cancer med Empliciti. Article | Follow @CarlyHFierce

> Novo touts SGLT2-topping data for blockbuster Victoza. Story

> GSK jumps on the 'smart inhaler' bandwagon with Ellipta sensor deal. Report

> Americans point fingers at Big Pharma over dramatic drug price increases. Article

Biotech Research News

> UCLA scientist points to pregnancy hormone as a safe, simple MS therapy. Article

> Scripps team partially corrects impact of a cystic fibrosis mutation. More

> Rockefeller researchers study a new approach to controlling nicotine addiction. Story

> BRCA1 is back in the spotlight, this time for Alzheimer's disease. Report

> New class of antimicrobials may be highly potent against MRSA. Article

Vaccines News

> Parents may be misled by inaccurate HPV vaccine websites, report says. Item

> NIAID to bring Chikungunya vaccine into Phase II. Report

> Valneva's C. diff vaccine found to be 'highly immunogenic' in PhII. Article

> Sanofi, Shantha to supply polio vaccines for India's universal immunization scheme. More

> FDA approves Seqirus' Fluad, the first U.S. boosted flu vaccine. Story

Pharma Marketing News

> Novo Nordisk strikes back with SGLT2-beating data on Victoza. Story

> Study finds no shortage of misleading HPV vaccine websites. Item

> Amgen biosim advances toward battle with AbbVie's mega-selling Humira. Report

> Pfizergan headed for top of ad-spend leaderboard--and not just in pharma. Article

> Ex-Sanofi staffer adds new allegations to last year's kickback suit. More

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Harvard scientists showed that a three-gene cocktail, by epigenetic reprogramming, could reverse the aging clock in mice retina nerve cells.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.